Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses

DSpace/Manakin Repository

Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses

Citable link to this page

 

 
Title: Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses
Author: Pawlak, Amanda C.; Cosper, Arjola K.; Deng, April; Horick, Nora K.; Le, Long Phi; Dias-Santagata, Dora; Selim, M. Angelica; Iafrate, Anthony John; Hoang, Mai P; Mihm, Martin Charles; Nguyen, Anh Thu

Note: Order does not necessarily reflect citation order of authors.

Citation: Le, Long P., Dora Dias-Santagata, Amanda C. Pawlak, Arjola K. Cosper, Anh Thu Nguyen, M. Angelica Selim, April Deng et al. 2012. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS ONE 7(10): e47290.
Full Text & Related Files:
Abstract: Apocrine-eccrine carcinomas are rare and associated with poor prognosis. Currently there is no uniform treatment guideline. Chemotherapeutic drugs that selectively target cancer-promoting pathways may complement conventional therapeutic approaches. However, studies on genetic alterations and EGFR and Her2 status of apocrine-eccrine carcinomas are few in number. In addition, hormonal studies have not been comprehensive and performed only on certain subsets of apocrine-eccrine carcinomas. To investigate whether apocrine-eccrine carcinomas express hormonal receptors or possess activation of oncogenic pathways that can be targeted by available chemotherapeutic agent we performed immunohistochemistry for AR, PR, ER, EGFR, and HER2 expression; fluorescence in situ hybridization (FISH) for EGFR and ERBB2 gene amplification; and molecular analyses for recurrent mutations in 15 cancer genes including AKT-1, EGFR, PIK3CA, and TP53 on 54 cases of apocrine-eccrine carcinomas. They include 10 apocrine carcinomas, 7 eccrine carcinomas, 9 aggressive digital papillary adenocarcinomas, 10 hidradenocarcinomas, 11 porocarcinomas, 1 adenoid cystic carcinoma, 4 malignant chondroid syringomas, 1 malignant spiradenoma, and 1 malignant cylindroma. AR, ER, PR, EGFR and HER2 expression was seen in 36% (19/53), 27% (14/51), 16% (8/51), 85% (44/52) and 12% (6/52), respectively. Polysomy or trisomy of EGFR was detected by FISH in 30% (14/46). Mutations of AKT-1, PIK3CA, and TP53 were detected in 1, 3, and 7 cases, respectively (11/47, 23%). Additional investigation regarding the potential treatment of rare cases of apocrine-eccrine carcinomas with PI3K/Akt/mTOR pathway inhibitors, currently in clinical testing, may be of clinical interest.
Published Version: doi:10.1371/journal.pone.0047290
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467209/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10528303
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters